This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or a tumour necrosis factor-alpha inhibitor (e.g., adalimumab or etanercept) at NHS hospitals in the United Kingdom. Information from patients' medical records will be collected, and patients will complete surveys about their experiences with their treatment. The study will look at treatment effectiveness from both healthcare professionals' and patients' points of view.
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the study period.
Study Type
OBSERVATIONAL
Enrollment
700
This is an observational study based on existing treatments prescribed prior to inclusion. No interventions are given as part of this research.
Royal National Hospital for Rheumatic Diseases
Bath, Somerset, United Kingdom
RECRUITINGNumber of participants that have achieved Low Disease Activity (LDA) at 12 months.
Time frame: At 12 months
Number of participants that have achieved Minimal Disease Activity (MDA) at 12 months.
Time frame: At 12 months
Change from baseline in PROM scores at 12 months.
Time frame: At 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.